Literature DB >> 21537082

A dual role for the immune response in a mouse model of inflammation-associated lung cancer.

Michael Dougan1, Danan Li, Donna Neuberg, Martin Mihm, Paul Googe, Kwok-Kin Wong, Glenn Dranoff.   

Abstract

Lung cancer is the leading cause of cancer death worldwide. Both principal factors known to cause lung cancer, cigarette smoke and asbestos, induce pulmonary inflammation, and pulmonary inflammation has recently been implicated in several murine models of lung cancer. To further investigate the role of inflammation in the development of lung cancer, we generated mice with combined loss of IFN-γ and the β-common cytokines GM-CSF and IL-3. These immunodeficient mice develop chronic pulmonary inflammation and lung tumors at a high frequency. Examination of the relationship between these tumors and their inflammatory microenvironment revealed a dual role for the immune system in tumor development. The inflammatory cytokine IL-6 promoted optimal tumor growth, yet wild-type mice rejected transplanted tumors through the induction of adaptive immunity. These findings suggest a model whereby cytokine deficiency leads to oncogenic inflammation that combines with defective antitumor immunity to promote lung tumor formation, representing a unique system for studying the role of the immune system in lung tumor development.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21537082      PMCID: PMC3104747          DOI: 10.1172/JCI44796

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

1.  gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis.

Authors:  Julia Bollrath; Toby J Phesse; Vivian A von Burstin; Tracy Putoczki; Moritz Bennecke; Trudie Bateman; Tim Nebelsiek; Therese Lundgren-May; Ozge Canli; Sarah Schwitalla; Vance Matthews; Roland M Schmid; Thomas Kirchner; Melek C Arkan; Matthias Ernst; Florian R Greten
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

2.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer.

Authors:  Sergei Grivennikov; Eliad Karin; Janos Terzic; Daniel Mucida; Guann-Yi Yu; Sivakumar Vallabhapurapu; Jürgen Scheller; Stefan Rose-John; Hilde Cheroutre; Lars Eckmann; Michael Karin
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

3.  IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway.

Authors:  Lin Wang; Tangsheng Yi; Marcin Kortylewski; Drew M Pardoll; Defu Zeng; Hua Yu
Journal:  J Exp Med       Date:  2009-06-29       Impact factor: 14.307

4.  T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis.

Authors:  Elias Gounaris; Nichole R Blatner; Kristen Dennis; Fay Magnusson; Michael F Gurish; Terry B Strom; Philipp Beckhove; Fotini Gounari; Khashayarsha Khazaie
Journal:  Cancer Res       Date:  2009-07-01       Impact factor: 12.701

5.  CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages.

Authors:  David G DeNardo; Jairo B Barreto; Pauline Andreu; Lesley Vasquez; David Tawfik; Nikita Kolhatkar; Lisa M Coussens
Journal:  Cancer Cell       Date:  2009-08-04       Impact factor: 31.743

Review 6.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

Review 7.  Myeloid-derived suppressor cells: linking inflammation and cancer.

Authors:  Suzanne Ostrand-Rosenberg; Pratima Sinha
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

8.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

Review 9.  Immune therapy for cancer.

Authors:  Michael Dougan; Glenn Dranoff
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

10.  Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma.

Authors:  Etienne Meylan; Alison L Dooley; David M Feldser; Lynn Shen; Erin Turk; Chensi Ouyang; Tyler Jacks
Journal:  Nature       Date:  2009-10-21       Impact factor: 49.962

View more
  45 in total

1.  Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation.

Authors:  Jingjiao Zhou; Zhaoxia Qu; Fan Sun; Lei Han; Liwen Li; Shapei Yan; Laura P Stabile; Lin-Feng Chen; Jill M Siegfried; Gutian Xiao
Journal:  Cancer Immunol Res       Date:  2017-01-20       Impact factor: 11.151

2.  Cell-selective inhibition of NF-κB signaling improves therapeutic index in a melanoma chemotherapy model.

Authors:  Thomas Enzler; Yasuyo Sano; Min-Kyung Choo; Howard B Cottam; Michael Karin; Hensin Tsao; Jin Mo Park
Journal:  Cancer Discov       Date:  2011-11       Impact factor: 39.397

Review 3.  An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.

Authors:  Stephanie C Casey; Yulin Li; Dean W Felsher
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

4.  Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma.

Authors:  Hongzheng Zhang; Sungjin Kim; Zhengjia Chen; Sreenivas Nannapaneni; Amy Y Chen; Charles E Moore; Gabriel Sica; Marina Mosunjac; Minh Ly T Nguyen; Gypsyamber D'Souza; Thomas E Carey; Lisa A Peterson; Jonathan B McHugh; Martin Graham; Christine M Komarck; Gregory T Wolf; Heather M Walline; Emily Bellile; James Riddell; Sara I Pai; David Sidransky; William H Westra; William N William; J Jack Lee; Adel K El-Naggar; Robert L Ferris; Raja Seethala; Jennifer R Grandis; Zhuo Georgia Chen; Nabil F Saba; Dong M Shin
Journal:  Head Neck       Date:  2017-09-25       Impact factor: 3.147

5.  Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.

Authors:  Esra A Akbay; Shohei Koyama; Yan Liu; Ruben Dries; Lauren E Bufe; Michael Silkes; Md Maksudul Alam; Dillon M Magee; Robert Jones; Masahisa Jinushi; Meghana Kulkarni; Julian Carretero; Xiaoen Wang; Tiquella Warner-Hatten; Jillian D Cavanaugh; Akio Osa; Atsushi Kumanogoh; Gordon J Freeman; Mark M Awad; David C Christiani; Raphael Bueno; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal:  J Thorac Oncol       Date:  2017-05-06       Impact factor: 15.609

6.  Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs.

Authors:  David I Bellovin; Bikul Das; Dean W Felsher
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 7.  Experimental mouse tumour models: what can be learnt about human cancer immunology?

Authors:  Glenn Dranoff
Journal:  Nat Rev Immunol       Date:  2011-12-02       Impact factor: 53.106

8.  Interleukin-6 cytokine: a multifunctional glycoprotein for cancer.

Authors:  Paul Zarogoulidis; Lonny Yarmus; Kaid Darwiche; Robert Walter; Haidong Huang; Zhigang Li; Bojan Zaric; Kosmas Tsakiridis; Konstantinos Zarogoulidis
Journal:  Immunome Res       Date:  2013-08-12

9.  The tobacco carcinogen nitrosamine induces a differential gene expression response in tumour susceptible A/J and resistant C3H mouse lungs.

Authors:  William Gordon; Valentin Galitovskiy; Robert Edwards; Bogi Andersen; Sergei A Grando
Journal:  Eur J Cancer       Date:  2012-09-23       Impact factor: 9.162

Review 10.  Inflammatory networks and immune surveillance of pancreatic carcinoma.

Authors:  Robert H Vonderheide; Lauren J Bayne
Journal:  Curr Opin Immunol       Date:  2013-02-17       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.